OHDSI Podcast: Jenny Lane Discusses Journey Of Hydroxychloroquine, the Lancet Rheumatology Paper and More in Debut Episode

Jenny Lane, co-lead author of the recently published “Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study,” discussed the study and the 2020 journey of hydroxychloroquine during the debut episode of the OHDSI podcast, which is available below, as well as on Apple Podcasts, Podbean and other podcast apps.

Lane opens with a discussion on everything that went into the study, which was generated during the OHDSI COVID-19 study-a-thon in March, but she also talks about her own personal connection to hydroxychloroquine and its connection with rheumatoid arthritis, as well as the early clinical and methodological impact of the study during its preprint stage. She also discusses how open science and collaboration impacted this global study, and she provided insight on a recent OHDSI preprint she led, a study on the risk of depression, suicide and other psychological impacts in hydroxychloroquine treatment.

You can read more about the study here.

You can listen to the podcast below. Following a brief introduction, Jenny Lane joins the podcast at the 1:55 mark.